{
    "root": "d5479215-dc0c-4fb3-bbec-01645d675e7c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "divalproex sodium",
    "value": "20250310",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "POVIDONE K29/32",
            "code": "390RMW2PEQ"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "HYPROMELLOSE 2910 (50 MPA.S)",
            "code": "1IVH67816N"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        }
    ],
    "indications": "divalproex sodium delayed-release tablets anti-epileptic indicated : treatment manic episodes associated bipolar disorder ( 1.1 ) monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1.2 ) prophylaxis migraine headaches ( 1.3 )",
    "contraindications": "divalproex sodium delayed-release tablets intended oral . divalproex sodium delayed-release tablets swallowed whole crushed chewed . patients informed take divalproex sodium delayed-release tablets every day prescribed . dose missed taken soon possible , unless almost time next dose . dose skipped , patient double next dose .",
    "warningsAndPrecautions": "divalproex sodium delayed-release tablets , usp supplied : 125 mg tablets ( valproic acid ) : white white colored modified oval biconvex enteric film coated tablets imprinted \u201c 511 \u201d one side black ink plain side . bottles 30\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . . ndc 69452-433-13bottles 100\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 ndc 69452-433-20bottles 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 ndc 69452-433-30 250 mg tablets ( valproic acid ) : pale brown colored mottled appearance modified oval biconvex enteric film coated tablets imprinted \u201c 512 \u201d one side black ink plain side . bottles 30\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . . ndc 69452-434-13bottles 100\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 ndc 69452-434-20bottles 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 ndc 69452-434-30 500 mg tablets ( valproic acid ) : blue colored modified oval biconvex enteric film coated tablets imprinted \u201c 513 \u201d one side black ink plain side . bottles 30\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 . . ndc 69452-435-13bottles 100\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 ndc 69452-435-20bottles 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 ndc 69452-435-30 recommended storage : store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature ] .",
    "adverseReactions": "divalproex sodium delayed-release tablets administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . divalproex sodium delayed-release tablets contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . divalproex sodium delayed-release tablets contraindicated patients known hypersensitivity [ ( 5.12 ) ] . divalproex sodium delayed-release tablets contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . prophylaxis migraine headaches : divalproex sodium delayed-release tablets contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Divalproex sodium delayed-release tablets are an anti-epileptic drug indicated for: Treatment of manic episodes associated with bipolar disorder (1.1) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1.2) Prophylaxis of migraine headaches (1.3)",
    "contraindications_original": "Divalproex sodium delayed-release tablets are intended for oral administration. Divalproex sodium delayed-release tablets should be swallowed whole and should not be crushed or chewed.\n                  Patients should be informed to take divalproex sodium delayed-release tablets every day as prescribed. If a dose is missed it should be taken as soon as possible, unless it is almost time for the next dose. If a dose is skipped, the patient should not double the next dose.",
    "warningsAndPrecautions_original": "Divalproex sodium delayed-release tablets, USP are supplied as:\n                  125 mg tablets (as valproic acid): White to off white colored modified oval biconvex enteric film coated tablets imprinted with \u201c511\u201d on one side in black ink and plain on the other side.\n                  Bottles of 30\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. NDC 69452-433-13Bottles of 100\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 NDC 69452-433-20Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 NDC 69452-433-30\n                  250 mg tablets (as valproic acid) : Pale brown colored with mottled appearance modified oval biconvex enteric film coated tablets imprinted with \u201c512\u201d on one side in black ink and plain on the other side.\n                  Bottles of 30\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. NDC 69452-434-13Bottles of 100\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 NDC 69452-434-20Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 NDC 69452-434-30\n                  500 mg tablets (as valproic acid): Blue colored modified oval biconvex enteric film coated tablets imprinted with \u201c513\u201d on one side in black ink and plain on the other side.\n                  Bottles of 30\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.. NDC 69452-435-13Bottles of 100\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 NDC 69452-435-20Bottles of 500\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 NDC 69452-435-30\n                  Recommended Storage: Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Divalproex sodium delayed-release tablets should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].\n                     \n                     Divalproex sodium delayed-release tablets are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].\n                     \n                     Divalproex sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].\n                     \n                     Divalproex sodium delayed-release tablets are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].\n                     \n                     For use in prophylaxis of migraine headaches: Divalproex sodium delayed-release tablets are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)]."
}